Lexaria Bioscience (LEXX) Cash & Equivalents (2010 - 2026)

Lexaria Bioscience has disclosed Cash & Equivalents across 17 years of filings, most recently posting $5.1 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $5.1 million, down 20.73% year-over-year; the trailing twelve-month figure through Feb 2026 was $5.1 million (down 20.73% YoY), and the FY2025 annual result was $1.8 million, down 72.27% from the prior year.
• Cash & Equivalents came in at $5.1 million for Q1 2026 at Lexaria Bioscience, up from $4.3 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $8.5 million in Q2 2024 to a low of $1.4 million in Q3 2023.
• The 5-year median for Cash & Equivalents is $4.7 million (2024), against an average of $5.0 million.
• Across the five-year window, Cash & Equivalents tumbled 76.74% in 2023 and jumped 380.72% in 2024, its largest moves.
• Lexaria Bioscience's Cash & Equivalents stood at $4.5 million in 2022, then plunged by 56.89% to $2.0 million in 2023, then surged by 313.39% to $8.1 million in 2024, then sank by 47.0% to $4.3 million in 2025, then grew by 19.78% to $5.1 million in 2026.
• The last three Cash & Equivalents figures came in at $5.1 million (Q1 2026), $4.3 million (Q4 2025), and $1.8 million (Q3 2025), per Business Quant data.